Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016

Aims: Registries on in-hospital drug use are sparse, especially those that can be linked to nationwide registries. In this study, we present and validate the Electronic Patient Medication module (EPM)—the electronic administrative database on in-hospital drug use covering the Capital Region of Denmark. Methods: The research database (EPM-research) is an adaptation of the database underlying the electronic administrative database for in-hospital drug use (EPM-clinic). The validation study was comprised of two sub-studies. Sub-study 1: Accordance of registration between EPM-clinic and EPM-research was investigated by analyzing randomly chosen retrospective patient records. Sub-study 2: Workflows and real-life registration practices were investigated through visits to three different (two medical and one emergency) departments. An observer followed a nurse while dispensing and administering drugs. This information was compared with EPM-research. The primary endpoint for both sub-studies was accordance of generic name between registrations. Secondary endpoints were exact brand name, dose, and time of each administration. Accordance (proportions) with 95% confidence intervals (CI) using the Clopper-Pearson method were calculated. The study was approved by the Danish Data Protection Agency (BFH-2016-058-04906) and the Danish Patient Safety Authority (3-3013-1884/1/). Results: In sub-study 1 227 retrospective drug administrations were reviewed. Accordance of generic name was 100.0% (CI 98.4%−100.0%). In sub-study 2 176 drug administrations were observed of which 173 were recorded with identical generic name, resulting in 98.3% (CI 95.1%-99.6%) accordance of data. Conclusions: Our validation of the EPM-research showed very high accordance. With detailed information on in-hospital drug use, the EPM-research may be a useful tool in pharmacoepidemiological research.

Download Full-text

Clinical and laboratory testing of oral anticoagulation therapy vitamin k antagonists at the emergency department of Hanoi Heart Hospital

Tạp chí Phẫu thuật Tim mạch và Lồng ngực Việt Nam ◽

10.47972/vjcts.v35i.698 ◽

2022 ◽

Vol 35 ◽

pp. 176-187

Author(s):

Nguyen Van Thuc ◽

Tran Thanh Hoa ◽

Dinh Hai Nam ◽

Nguyen Van Quy ◽

Vu Dinh Hung ◽

...

Keyword(s):

Emergency Department ◽

Drug Use ◽

Vitamin K ◽

Vitamin K Antagonists ◽

Common Factor ◽

Anticoagulation Therapy ◽

Current Status ◽

Coagulation Disorders ◽

Brand Name ◽

Heart Hospital

Background: The most commonly used oral anticoagulant is acenocoumarol with the brand name is Sintrom and recently, warfarin with the brand name is Coumadin has begun to be used. Anticoagulation with vitamin K antagonists faces two main obstacles: the narrow therapeutic range and the effectiveness of the drug varies by many factors. Objective: " Current status of coagulation disorders in the treatment of anticoagulants with vitamin K antagonists. Understanding some factors affecting the goal of anticoagulant treatment". Method: Cross-sectional, retrospective, descriptive analysis of drug use and influencing factors of patients diagnosed with coagulopathy admitted to the emergency department at Hanoi Heart Hospital from April 2020 to August 2021. Results: There were 675 patients admitted to the hospital with blood clotting disorders. The average age is 60,17±10,13, the youngest is 30, the oldest is 90; 63 patients, accounting for 9.42%, need to be hospitalized for inpatient treatment; There are 108 patients, accounting for 16%, with bleeding and 18 patients, accounting for 2.7%, with thromboembolism or valve obstruction. Conclusion: Coagulation disorders during treatment with vitamin K antagonist anticoagulants is a common condition in the emergency department. However, the complication rate is not high. There are many factors that affect the patient's treatment goals and the drug use is a fairly common factor.

Download Full-text

Drug Use Patterns in Severely Mentally Ill Medicare Beneficiaries: Impact of Discontinuities in Drug Coverage

Health Services Research ◽

10.1111/j.1475-6773.2007.00779.x ◽

2008 ◽

Vol 43 (2) ◽

pp. 496-514 ◽

Cited By ~ 11

Author(s):

Linda Simoni-Wastila ◽

Ilene H. Zuckerman ◽

Thomas Shaffer ◽

Christopher M. Blanchette ◽

Bruce Stuart

Keyword(s):

Drug Use ◽

Mentally Ill ◽

Drug Coverage ◽

Medicare Beneficiaries ◽

Use Patterns ◽

Severely Mentally Ill ◽

Drug Use Patterns

Download Full-text

Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?

Health Affairs ◽

10.1377/hlthaff.2018.05476 ◽

2019 ◽

Vol 38 (7) ◽

pp. 1188-1194 ◽

Cited By ~ 8

Author(s):

Stacie B. Dusetzina ◽

Shelley Jazowski ◽

Ashley Cole ◽

Joehl Nguyen

Keyword(s):

Medicare Beneficiaries ◽

Brand Name ◽

Brand Name Drugs

Download Full-text

Spending and Utilization on Drugs Prescribed by Otolaryngologists to Medicare Beneficiaries, 2013 to 2017

Annals of Otology Rhinology & Laryngology ◽

10.1177/00034894211050434 ◽

2021 ◽

pp. 000348942110504

Author(s):

Shivani A. Shah ◽

Lauren E. Miller ◽

Roy Xiao ◽

Alan Workman ◽

Lucy Xu ◽

...

Keyword(s):

Medicare Part D ◽

Relative Increase ◽

Medicare Part ◽

Prescription Data ◽

Annual Growth Rate ◽

Medicare Beneficiaries ◽

Brand Name ◽

Part D ◽

Relative Decrease ◽

Brand Name Drugs

Objectives: The significant and rising cost of prescription drugs is a pressing concern for patients and payers. However, little is known about spending on and utilization of drugs prescribed by otolaryngologists. Methods: Utilizing publicly available Medicare Part D Prescriber Public Use data, we conducted a retrospective cross-sectional analysis of 34 small-molecule drugs commonly prescribed by otolaryngologists (defined as 2017 Medicare Part D spending ≥$500 000) to Medicare beneficiaries. Prescription data was characterized by drug type (brand name vs generic). Primary outcomes for each prescription drug included the total annual cost and the total annual number of days supplied. Results: From 2013 to 2017, spending on drugs prescribed by otolaryngologists to Medicare beneficiaries decreased by $32.1 million ($131.7–$99.5 million; relative decrease 24.4%; compound annual growth rate [CAGR] −5.4%), while total utilization increased by 24.9 million days supplied (74.6–99.5 million; relative increase 33.3%; CAGR 5.9%). For brand name drugs, there was a decrease in spending ($71.1–$26.7 million; relative decrease −62.4%; CAGR −17.8%) and utilization (11.2–3.1 million days supplied; relative decrease −72.5%; CAGR −22.8%). In contrast, generic drugs demonstrated increased spending ($60.6–$72.8 million; relative increase 20.2%; CAGR 3.7%) and utilization (63.5–96.4 million days supplied; relative increase 51.9%; CAGR 8.7%). Conclusions: Spending on drugs prescribed by otolaryngologists to Medicare Part D beneficiaries declined between 2013 and 2017 in part due to a transition from brand name drugs to lower-cost generic equivalents.

Download Full-text